U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H4O4.Ca
Molecular Weight 156.15
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM SUCCINATE ANHYDROUS

SMILES

[Ca++].[O-]C(=O)CCC([O-])=O

InChI

InChIKey=PBUBJNYXWIDFMU-UHFFFAOYSA-L
InChI=1S/C4H6O4.Ca/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2

HIDE SMILES / InChI
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

1921
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
503
Unknown

Approved Use

Unknown
Palliative
Phase I
424
Unknown

Approved Use

Unknown
Palliative
Phase I
424
Unknown

Approved Use

Unknown
Primary
Approved
8360
Unknown

Approved Use

Hypocalcemia, chronic (treatment) ā€” Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors.
1999 Feb 26
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
1999 Jun 24
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.
2000 Aug
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V.
2000 Feb 11
alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties.
2000 Jan 1
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
2000 Jan 7
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.
2000 Nov
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.
2000 Nov
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension.
2000 Sep
Chemokines induce eosinophil degranulation through CCR-3.
2000 Sep
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.
2000 Sep
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001 Aug
Complement activation in factor D-deficient mice.
2001 Dec 4
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.
2001 Jul
[Acute renal failure caused by hypercalcemia].
2001 Jun 10
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.
2001 Mar 2
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses.
2001 Mar 27
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
2001 Oct
Familial intrahepatic cholestasis 1: studies of localization and function.
2001 Oct
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.
2001 Oct 12
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.
2001 Sep
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.
2001 Sep 1
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.
2002
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.
2002 Jul 5
Expression of functional CCR and CXCR chemokine receptors in podocytes.
2002 Jun 15
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice.
2002 Mar 15
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.
2002 Nov 4
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.
2002 Sep 6
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
2002 Sep 6
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.
2003 Jan
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate].
2006 Oct
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.
2006 Oct 20
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans.
2012 Apr
Effect of calcium phosphate and vitamin Dā‚ƒ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.
2014 Jan 17
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.
2015 Aug 12
Lactose behaviour in the presence of lactic acid and calcium.
2016 Aug
Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate.
2018 Mar
Patents

Patents

03966773
137
03974176
69
03981818
92
04008309
69
04028407
67
04041173
67
04042702
67
04058507
67
04063023
67
06485737
67
06497902
67
08637538
67
20090030026
67
20130174651
67
JP2017071731
67
US2143359
67

Sample Use Guides

In Vivo Use Guide
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:41:28 UTC 2023
Edited
by admin
on Thu Jul 06 02:41:28 UTC 2023
Record UNII
P455B96DTZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM SUCCINATE ANHYDROUS
Common Name English
BUTANEDIOIC ACID, CALCIUM SALT (1:1)
Common Name English
SUCCINIC ACID, CALCIUM SALT (1:1)
Common Name English
CALCIUM SUCCINATE [USP-RS]
Common Name English
CALCIUM SUCCINATE [MI]
Common Name English
Calcium succinate [WHO-DD]
Common Name English
Code System Code Type Description
CAS
140-99-8
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
MERCK INDEX
M2977
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY Merck Index
FDA UNII
P455B96DTZ
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
RS_ITEM_NUM
1087360
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
EPA CompTox
DTXSID90883329
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
PUBCHEM
159605
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-445-6
Created by admin on Thu Jul 06 02:41:28 UTC 2023 , Edited by admin on Thu Jul 06 02:41:28 UTC 2023
PRIMARY
Related Record Type Details
Structure of CALCIUM SUCCINATE
SOLVATE->ANHYDROUS
Structure of SUCCINIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CALCIUM CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 ā€¢ 301-594-8966